NGAL (also known as Lipocalin-2 or Neutrophil Gelatinase-associated Lipocalin) is a small, ~25kDa secreted protein expressed in epithelial tissues throughout the body.
An AKI biomarker lipocalin 2 in the blood derives from the kidney in renal injury but from neutrophils in normal and infected conditions: J. Kanda, et al.; Clin. Exp. Nephrol. 19, 99 (2015), Abstract;
Lipocalin 2 deficiency dysregulates iron homeostasis and exacerbates endotoxin-induced sepsis: G. Srinivasan, et al.; J. Immunol. 189, 1911 (2012), Abstract;
LIPOCALIN-2 is a major acute-phase protein in a rat and mouse model of sterile abscess: S. Sultan, et al.; Shock 37, 191 (2012), Abstract;
Mild elevation of urinary biomarkers in prerenal acute kidney injury: K. Doi, et al.; Kidney Int. 82, 1114 (2012), Abstract;
Establishment of acute kidney injury mouse model by 0.75% adenine ingestion: Y. Morishita, et al.; Ren. Fail. 33, 1013 (2011), Abstract;
MCP-1 gene activation marks acute kidney injury: R. Munshi, et al.; J. Am. Soc. Nephrol. 22, 165 (2011), Abstract;
Renal cortical albumin gene induction and urinary albumin excretion in response to acute kidney injury: L.B. Ware, et al.; Am. J. Physiol. Renal Physiol. 300, F628 (2011), Abstract;
Lipocalin 2 is essential for chronic kidney disease progression in mice and humans: A. Viau, et al.; J. Clin. Invest. 120, 4065 (2010), Abstract;
General Literature References
Application of emerging biomarkers of acute kidney injury in development of kidney-sparing polypeptide-based antibiotics: D. Burt, et al.; Drug Chem. Toxicol. 37, 204 (2014), Abstract;
Ultra sensitive (1.279 pg/ml) ELISA kit, enabling reduced input sample and matrix interference, for the quantification of KIM-1, an early biomarker for kidney injury or disease.
